Jobs / United States / Stoke Therapeutics INC

Stoke Therapeutics INC

Vice President, Clinical Development - Ophthalmology

Bedford, Massachusetts, United States Posted today

Apply on employer site ↗ Tailor my CV first Source: Company careers site

Optional: we can tailor a CV and cover letter for this job from your real experience first (the first one is free).

Sponsorship verdict

Sponsorship possible

One solid signal, not two. Worth applying, and worth asking about sponsorship early.

  • Employer is on a government sponsor recordThe US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Mar 2026) — the step every H-1B hire needs first.
  • The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
  • No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
  • Confirmed live todayWhen a source last listed this job as open.
Details and sources
Employer is on a government sponsor record
The US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Mar 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
No salary bar for this route
H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.

US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).

A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.

About the role

About Stoke: Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ Position Purpose: The Vice President of Clinical Development, Ophthalmology will provide strategic and operational leadership for the clinical development of the company's ophthalmology pipeline, with a particular focus on innovative therapies for rare and genetic retinal diseases. This executive will be responsible for designing and executing global clinical development strategies spanning early-stage through registrational programs, working closely with Research, Regulatory Affairs, Clinical Operations, Biostatistics, Medical Affairs, and Commercial teams. The successful candidate will be an experienced physician leader with deep expertise in ophthalmology drug development and a demonstrated track record advancing novel therapies through clinical proof-of-concept, pivotal studies, and regulatory submissions. Experience in rare diseases, inherited retinal disorders, gene therapy or other advanced therapeutic modalities is strongly preferred. Key Responsibilities: Clinical Development Leadership: • Lead the clinical development strategy for ophthalmology programs from IND-enabling activities through registration and life-cycle management. • Serve as the medical and scientific leader for assigned development programs, ensuring alignment with corporate objectives and portfolio strategy. • Design and oversee Phase 1-3 clinical trials, including protocol development, endpoint selection, statistical considerations, and clinical study interpretation. • Provide strategic leadership for regulatory interactions, including FDA, EMA, PMDA, and other global health authorities. • Drive development plans that maximize the probability of technical, clinical, regulatory, and commercial success. Cross-Functional Leadership: • Partner closely with Clinical Operations, Biostatistics, Regulatory Affairs, Translational Medicine, Medical Affairs, and Commercial teams to ensure successful program execution. • Serve as Program representative on the Ophthalmology Program Team • Chair clinical development teams and governance committees as appropriate. • Build and maintain strong relationships with key opinion leaders, investigators, patient advocacy groups, and strategic partners. • Support business development activities. Team Development: • Recruit, develop, and mentor clinical scientists and physician leaders. • Foster a culture of scientific excellence, collaboration, accountability, and patient focus. • Establish best practices for clinical development and medical governance across the organization. Required Skills & Experience: • M.D. or M.D./Ph.D. degree required. • Board certification in Ophthalmology is strongly preferred. • Minimum of 12-15 years of biopharmaceutical industry experience, including substantial clinical development leadership responsibilities. •

Apply on employer site ↗